

NovaBay Pharmaceuticals

17:47 25 Oct 2010

NovaBay Pharmaceuticals delivers positive results for two anti-microbial drug studies

Biotech company NovaBay Pharmaceuticals (NYSE Amex:NBV) said Monday that data from two separate studies for the company's Aganocide compounds delivered "compelling" results against impetigo, a bacterial infection of the skin, and nail fungus infection, respectively.

NovaBay's Aganocide compounds are anti-microbial compounds designed to mimic the body's natural defense against infection. The compounds are currently being studied in both preclinical and clinical programs, and have the potential to address the growing problem of antibiotic resistance, said the company.

The first study by NovaBay was designed to evaluate the efficacy and safety of three different strengths of NVC-422 Topical Gel in the treatment of impetigo.

Impetigo is a highly contagious superficial bacterial infection of the skin that affects mostly children, and multi-drug resistant strains such as MRSA are being observed with increasing frequency in this population.

129 children ranging from 2-12 years of age were tested, and clinical and bacteriological response rates for the three concentrations ranged from 84% to 95% at the end of treatment and at follow up. Notably, response rates for MRSA infections were 100% across all treatment groups, said NovaBay.


During the second study, NVC-422 was tested to work against onychomycosis, a commonly diagnosed nail disorder. Topical treatment of the infection is currently limited, as available drugs fail to penetrate the human nail.

The new trial was conducted using an in vitro-infected human nail model, and showed that NVC-422 gel formulations could in fact penetrate and kill fungi grown on the subungual side of the infected nail.

NovaBay has a license and research collaboration agreement with Alcon for use of its Aganocide compounds to treat eye, ear and sinus infections, as well as for contact lens care. The company has also entered into a deal with Galderma to develop and commercialize Aganocide compounds in impetigo and other dermatological indications.

The company was up more than 1.5% on Monday, trading at \$1.94 at 12:12pm ET.

1 Year Share Price Graph



November 2019 June 2020 November 20

Share Information

Code: NBV
Listing: NYSEMKT
Sector: Pharma & Biotech
Website: novabay.com

Company Synopsis:

NovaBay Pharmaceuticals \$NBV is a biopharmaceutical company focusing, commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global eye care market.

action@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.